Here is the design of a clinical trial:

Official Title: Does the Glucagon-like Peptide-1 Receptor Agonist Semaglutide Prevent Deterioration of Metabolic State in Prediabetic or Diabetic Patients With Schizophrenia Treated With the Antipsychotic Compounds Clozapine or Olanzapine?

Included conditions:
- Metabolic Disturbance
- Schizophrenia
- Type 2 Diabetes
- Clozapine
- GLP-1
- Olanzapine

Study Armgroups:
- {'label': 'Semaglutide injection once-weekly', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Drug: Semaglutide, 1.34 mg/mL']}
- {'label': 'Semaglutide-Placebo injection once-weekly', 'type': 'PLACEBO_COMPARATOR', 'interventionNames': ['Drug: Semaglutide-placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'Semaglutide, 1.34 mg/mL', 'description': 'Semaglutide 1.34 mg/ml, 1.5 ml pre-filled pen-injector is supplied in pens for injection containing 2.0 mg of the GLP-1RA semaglutide in 1.5 ml sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Direction for use will be given together with trial products.The possible doses of semaglutide are 0.25 mg, 0.50 mg and 1.0 mg. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide will remain on 0.5 mg once-weekly. The injection is administered subcutaneously once-weekly.', 'armGroupLabels': ['Semaglutide injection once-weekly']}
- {'type': 'DRUG', 'name': 'Semaglutide-placebo', 'description': 'The semaglutide placebo pens contain "XX-vehicle" (no active drug) and are administered in the same way and volume as semaglutide. The semaglutide placebo is specially packed for this study and will be used in the study only. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide placebo will remain on 0.5 mg once-weekly. The injection is administered once-weekly. If the lowest tolerated dose is less than 0.5 mg of semaglutide placebo once-weekly, the patient will be excluded from the study.', 'armGroupLabels': ['Semaglutide-Placebo injection once-weekly']}

Primary Outcomes:
- {'measure': 'The primary endpoint is the change from baseline in glycated haemoglobin A1c (HbA1c).', 'timeFrame': '26 weeks'}

Please estimate the sample size based on the assumption: 
Significance level (α) of 5%, power (1−β) of 90%, and an expected dropout rate of 50%.
Sample size
        The study is an explanatory study and the required patient population size is based on significance level (Î±) of 5%, a power (1âÎ²) of 90%, where Î² (10%) is the risk of accepting a hypothesis that is false. Based on data from a recent study in similar patients,76 we estimated that the minimum relevant difference (MIREDIF) of HbA1c (primary endpoint) after 26 weeks of intervention would be â0.26% with an SD of 0.28%. With the aforementioned power, significance level, MIREDIF and SD, the trial requires 26 patients in each of the two arms, that is, a total of 52 patients. Thus, with an expected dropout of 50%, a total of 104 patients will be randomised.